Source content
FAA Guide for Aviation Medical Examiners · Version 10/28/2026 · page 217
CACI - Colitis Worksheet
(Updated 04/29/2026)
To determine the applicant’s eligibility for certification, the AME must review a current, detailed Clinical
Progress Note generated from a clinic visit with the treating physician or specialist no more than 90 days
prior to the AME exam. If the applicant meets ALL the acceptable certification criteria listed below, the
AME can issue. Applicants for first- or second-class must provide this information annually; applicants for
third-class must provide the information with each required exam.
AME MUST REVIEW ACCEPTABLE CERTIFICATION CRITERIA
A current, detailed [ ] Condition is stable with no effects that would interfere with flight
Clinical Progress Note duties, AND
from the treating [ ] No surgery for the condition in the last 6 (six) weeks.
physician
Symptoms [ ] None or mild diarrhea (less than 4 bowel movements/day) with or
without mild abdominal pain/cramping AND
[ ] No severe abdominal symptoms or fatigue which limits activity.
Cause of Colitis [ ] Crohn’s disease, ulcerative colitis, microscopic colitis, or irritable
bowel syndrome
Any other causes require an FAA decision.
Medications for [ ] One or more of the following:
• Guanylate Cyclase-C (GC-C) Agonist
condition
• linaclotide(Linzess), plecanatide (Trulance)
• Sodium/Hydrogen Exchanger 3 Inhibitor
• tenapanor (Ibsrela)
• Steroids
Oral formulations prednisone 20 mg/day equivalent or less (see steroid
conversion calculator)
Oral budesonide 9mg or less
KEY:
Steroid foams or enemas/ budesonide enema
Interleukin Inhibitors (IL)
• azathioprine (Imuran)
• hyoscyamine - use 1-2 times a week with no side effects and no-fly 72 hours
Phosphodiesterase-4
after use
Enzyme Inhibitor (PDE4)
• loperamide less than or equal to 16 mg a day and no side effects
Tumor necrosis factor
• mercaptopurine (6-MP)
inhibitors (TNF)
• mesalamine (Asacol, Pentasa, Lialda)
• methotrexate (Trexall)
Selective Adhesion-
• sulfasalazine (Azulfidine)
Molecule Inhibitor (SAM)
• Any single medication listed below after a 2-week ground trial and:
No post-dose observation time:
o JAK: tofacitinib (Xeljanz) and upadacitinib (Rinvoq)
4-hour post-dose observation time:
o TNF: adalimumab (Humira and all biosimilars),certolizumab
(Cimzia), golimumab (Simponi)
o IL: guselkumab (Tremfya), mirikizumab (Omvoh), risankizumab
(Skyrizi), ustekinumab (Stelara)
o SAM: vedolizumab (Entyvio)
24-hour post-dose observation time:
o TNF: infliximab (Inflectra, Remicade, Renflexis)
AME MUST NOTE in Block 60 one of the following:
[ ] CACI qualified colitis. (Documents do not need to be submitted to the FAA.)
[ ] Has current OR previous SI/AASI but now CACI qualified colitis.
[ ] NOT CACI qualified. I have deferred. (Submit supporting documents.)
FAA Guide for Aviation Medical Examiners, Version 10/28/2026, page 217. AME Copilot is an independent reference tool, not affiliated with or endorsed by the FAA. The FAA AME Guide is the authoritative source.